mantelzell-lymphom- aktuelle standards und studienkonzepte m. dreyling, dept. of medicine iii
DESCRIPTION
internet: www.lymphome.de • email: [email protected]. Symposium des KML * DGHO 2008 * Wien, 13. Oktober 2008. Mantelzell-Lymphom- Aktuelle Standards und Studienkonzepte M. Dreyling, Dept. of Medicine III Klinikum Grosshadern LMU/München. Mantle cell lymphoma (MCL). - PowerPoint PPT PresentationTRANSCRIPT
Mantelzell-Lymphom-
Aktuelle Standards
und Studienkonzepte
M. Dreyling, Dept. of Medicine III
Klinikum GrosshadernLMU/München
internet: www.lymphome.de • email: [email protected]
Symposium des KML * DGHO 2008 * Wien, 13. Oktober 2008
Mantle cell lymphoma (MCL)
• Morphology: small to intermediate size lymphoidcells with irregular, cleaved nuclei,cave: round cell, blastoid and pleomorphic variants
• Immunphenotype: sIg++, l > k , CD19/20/22+, CD5+, CD10-, CD23-, CD11c-, HLA-DR++, CD43+
• molecular/cytogenetics: t(11;14)(q13;q32); overexpression of cyclin D1
• clinical outcome: predominantly elderly, male patients,extranodal involvement,late stage, poor outcome
20%
83%
W. Ludwig, Berlin
Clinical risk factors: MIPI clinical
(PALL: PS, age, LDH, leucocyte count) Hoster, Blood 2008
young patient (<65) elderly patient (>65) compromised patient
First line treatment
conventionalimmuno-chemotherapy
(e.g. R-CHOP)
Rituximab maintenance ?radioimmunotherapy ?
watch & wait ?Rituximab
monotherapyChlorambucilBendamustin
1. relapse
high tumor load:immuno-chemotherapy
(e.g. R-FC)
allo-transplant ?radioimmunotherapy ?
Rituximab maintenance ?
immuno-chemotherapy(e.g. R-FC,
R-Bendamustin)
molecular approaches ? autologous PBSCT
radioimmunotherapy ? Rituximab maintenance ?
immuno-chemotherapy
(e.g. R-Bendamustin)
molecular approaches
higher relapse
molecular approaches: Bortezomib, CCI-779, Thalidomide/Lenalidomide, Flavopiridol (preferable in combination)
repeat previous therapy (long remissions)
dose-intensifiedimmuno-chemotherapy
(either sequential: e.g. R-CHOP =>PBSCT
or R-Hyper-CVAD)
Dreyling ASCO 2006
day 1 day 21
Rituximab + HyperCVAD/M-A in MCL
alternate cycles 1 and 2 every 21 days
Rituximab 375mg/m2 (day 1)
Methotrexate 200mg/m2 i.v. 2 hours (day 2)
Methotrexate 800mg/m2 i.v.continuous 22 h (day 2)
Cytarabine 1,000/3,000mg/m2 i.v. 2x 2h (days 3–4)
cycle 1, 3, 5, 7
R-hyperCVADcycle 2, 4, 6, 8
R-M-A
antifungal, antibacterial, antiviral prophylaxis: G-CSF !!!
Romaguera, JCO 2005
Mantle cell lymphoma
R-Hyper-CVAD
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5Years from Registration
At Risk
49
Progression
or Death
13
1-Year
Estimate
89%
Progression-free survival
Epner ASH 2007 #387
Mantle cell lymphoma
R-CHOP/High dose Ara-C => ASCT
B: Survival
0.0 2.5 5.0 7.5 10.00
20
40
60
80
100
MCL1 (n=41)P<0.001
MCL2 (n=160)
Years
Per
cen
t su
rviv
al
A: Event-free Survival proportions
0.0 2.5 5.0 7.5 10.00
20
40
60
80
100
MCL1 (n=41)
MCL2 (n=160)
P<0.0001
Years
Per
cen
t su
rviv
al
Geisler Blood 2008
European MCL Network
patients <65 years
PR, CR!
Cyclo 120mg/kg+ TBI 12 Gray
PBSCT
PR, CR!
3 x R-CHOP3 x R-DHAPalternating
(stem cell mobilization after
course 4)
PBSCT
TBI 10 GrayAra-C 4 x 1.5 g/m2
Melphalan 140 mg/m2
3 x R-CHOP
DexaBEAM(stem cell mobilization)
3 x R-CHOP
MCL Younger Response rate of induction
Documented response 189 55%
Abort without staging 2
CR 59 31%
CRu 40 21% CR+CRu: 52%
PR 73 39% CR+CRu+PR: 91%
SD 8 4%
PD 9 5%
ED 0 0%
MCL younger
Time to treatment failure
young patient (<65) elderly patient (>65) compromised patient
First line treatment
conventionalimmuno-chemotherapy
(e.g. R-CHOP)
Rituximab maintenance ?radioimmunotherapy ?
watch & wait ?Rituximab
monotherapyChlorambucilBendamustin
1. relapse
high tumor load:immuno-chemotherapy
(e.g. R-FC)
allo-transplant ?radioimmunotherapy ?
Rituximab maintenance ?
immuno-chemotherapy(e.g. R-FC,
R-Bendamustin)
molecular approaches ? autologous PBSCT
radioimmunotherapy ? Rituximab maintenance ?
immuno-chemotherapy
(e.g. R-Bendamustin)
molecular approaches
higher relapse
molecular approaches: Bortezomib, CCI-779, Thalidomide/Lenalidomide, Flavopiridol (preferable in combination)
repeat previous therapy (long remissions)
dose-intensifiedimmuno-chemotherapy
(either sequential: e.g. R-CHOP =>PBSCT
or R-Hyper-CVAD)
Dreyling ASCO 2006
European MCL network studies
patients >60 years
4 x R-CHOP
PR, CR
IFN-α maintenance(3 x 3 M IU/week)
or Peg-IFN(1mg/kg week)
4 x R-CHOP
PR, CR
3 x R-FC
Rituximabmaintenance
(all 2 months)
3 x R-FC
MCL Elderly
Response rate of induction
Documented Response 164 50%
Abort without staging 6
CR 55 35%
CRu 26 16% CR+CRu: 51%
PR 51 32% CR+CRu+PR: 84%
SD 5 3%
PD 19 9%
ED 6 4%
MCL elderly
Time to treatment failure
51 events
MCL elderly
Response duration in CR
4 events
young patient (<65) elderly patient (>65) compromised patient
First line treatment
conventionalimmuno-chemotherapy
(e.g. R-CHOP)
Rituximab maintenance ?radioimmunotherapy ?
watch & wait ?Rituximab
monotherapyChlorambucilBendamustin
1. relapse
high tumor load:immuno-chemotherapy
(e.g. R-FC)
allo-transplant ?radioimmunotherapy ?
Rituximab maintenance ?
immuno-chemotherapy(e.g. R-FC,
R-Bendamustin)
molecular approaches ? autologous PBSCT
radioimmunotherapy ? Rituximab maintenance ?
immuno-chemotherapy
(e.g. R-Bendamustin)
molecular approaches
higher relapse
molecular approaches: Bortezomib, CCI-779, Thalidomide/Lenalidomide, Flavopiridol (preferable in combination)
repeat previous therapy (long remissions)
dose-intensifiedimmuno-chemotherapy
(either sequential: e.g. R-CHOP =>PBSCT
or R-Hyper-CVAD)
Dreyling ASCO 2006
Bortezomib: Mechanism of action
26S proteasome:
degrades tagged proteins
Bortezomib:
reversible inhibitor
of the proteasome
Inhibition:prevents proteolysis of tagged proteins
Clinical studies: bortezomib cytotoxic to a variety of lymphomas !
Weigert Leukemia 2007
Bortezomib Ara-C combination in MCL
Efficacy in vitro
Weigert, ASH 2006
Bortezomib Ara-C combination in MCL
Pilot phase
European MCL network
relapsed MCL (DHAB = R-HAD)
Patients: n=250, relapsed MCL after/not appropriate for autologous PBSCT
Therapy: Dexamethasone 40 mg day 1-4 Rituximab 375 mg/m2 day 1 Ara-C 2 x 1–2 g/m2 day 2+/-Bortezomib 1,5 mg/m2 day 1, 4
Study aim: - Response rate- Progression-free/overall survival- Toxicity/feasability
Mantle cell lymphoma
Lenalidomide
HistologyPT
InitiBest
ResponseDay 4
Day 5
Day 20
Day 30
Day 50
Day 51
Day 53
Day 54
Day 58
Day 75
Day 89
Day 91
Day 104
Day 106
Day 108
Day 116
Day 117
Day 122
Day 135
Day 140
Day 170
Day 190
Day 222
Day 229
Day 239
Day 272
Day 373
FCL SB CRu 15 10
DLC BS Cru
DLC TP Cru 20
DLC KJS Cru 20
MCL SLR PR 20 15 10
MCL VFG PR 20 15
FCL GO PR
MCL BMF PR 20
DLC CD PR 20 15 10
MCL JMP PR 20
MCL LMM PR
TSF RE PR 20
MCL ERD PR
TSF KBA SD 20
DLC RA SD
DLC BP SD
DLC LG SD
MCL ET SD 20 15
DLC GAW SD
MCL GHM XPD 20
DLC OWF XPD 20 15
DLC JET XPD
DLC PC XPD
DLC RB XPD
MCL MR XPD
MCL TF XPD
DLC JAL XPD
MCL JES XPD
DLC RF XPD
DLC AD XPD
FCL RCS XPD
MCL FG XPD
CruPRSDPD
Wiernik ASH 2006
Feasability and efficacy of Lenalidomide maintenance after prior immuno-chemotherapy induction in relapsed
or refractory mantle cell lymphoma
Inclusion Criteria• Histologically proven MCL
• Not eligible / relapse after ASCT
• > 1 prior chemotherapy
RecruitmentN=60
Response
PD or Toxicity
Endpoints• Feasability• Duration of Response• TTP and PFS• OS• Safety
Salvage Therapy
R-FC(M)R-DHA(P)R-GemOx
Lenalidomide 15mg p.o/d
daily
Staging PR, CR
National centers: Essen, Homburg, Kiel, Mainz, GH-LMU, Tübingen, Ulm
European MCL Network
clinical intergroup working party
molecular markers
pathological review
virtual tumor bank
WHO/ Kiel criteria
pathology panel
phase III studies (first line)
phase II studies (relapse)
remission/survival data
immunostaining ofmolecular markers
central data base:analysis of predictive and prognostic risk factors
MRD/cytogenetics
pharmacogenomics
expression profiling
new molecular markers
patientblood sample
molecularanalysis
signal pathway of resistance
MRD
www.european-mcl.net
R-CHOP vs. R-FC
anti-CD20 vs. IFN
„Mini“ transplant
< 65 years > 65 years
R-CHOP vs. R-CHOP/DHAP
PBSCT
R-chemo +/- Bortezomib
1. Relapse < 65 years> 65 years
European MCL Network: Clinical studies 2008/9
2. Relapse (or not qualifying for R-HAD)
First line
Bendamustin/Temsirolimus
Radio-immuno
consolidation
Lenalidomide consolidation
Rad 001(mTOR)
www.european-mcl.net